By Fineline Cube 
Sirnaomics Ltd. (HKG: 2257) announced a strategic investment agreement with Bloomage Biotech (Hong Kong) Limited, a wholly‑owned subsidiary of Bloomage Biotech (SHA: 688363). Bloomage will subscribe to Sirnaomics’ placed shares at HK$12 per share, totaling approximately HK$138 million and acquiring roughly 9.44 % of Sirnaomics’ issued share capital.
Key Deal Highlights
- Investment Size – HK$138 million in placed shares at HK$12 each.
- Equity Stake – Bloomage will own about 9.44 % of Sirnaomics post‑transaction.
- Strategic Alignment – Enables Sirnaomics to reallocate internal resources toward oncology and autoimmune disease pipelines.
- Value Creation – Leverages Bloomage’s expertise to enhance Sirnaomics’ medical‑aesthetics portfolio.
Collaborative Innovation
- Technology Synergy – Sirnaomics’ proprietary PNP (Peptide Nanoparticle) and GalAhead delivery platforms will be combined with Bloomage’s research in hyaluronic acid and biologics.
- Product Roadmap – Joint development of a new generation of precision‑delivery therapeutics that target both cancer and autoimmune indications.
- Resource Allocation – Funding will accelerate preclinical and clinical milestones while expanding the company’s product breadth.
Market Implications
- Oncology Focus – The infusion of capital supports accelerated progression of Sirnaomics’ oncology candidates through Phase 2/3 studies.
- Autoimmune Expansion – Enhanced pipeline depth positions the company to capture a larger share of the growing autoimmune therapeutics market.
- Aesthetic Synergy – Bloomage’s established market presence in medical aesthetics provides an immediate commercial channel for Sirnaomics’ novel delivery technologies.
Forward‑Look
Sirnaomics plans to deploy the investment toward key clinical programs, while Bloomage Biotech will provide strategic guidance and market access. Both firms anticipate that the partnership will unlock significant long‑term shareholder value and accelerate the translation of cutting‑edge delivery platforms into clinically relevant therapies.-Fineline Info & Tech